Orthocell Ltd (AU:OCC)
ASX:OCC
OCC Stock Chart & Stats
AU$0.81
AU$0.07(4.58%)
At close: 4:00 PM EST
AU$0.81
AU$0.07(4.58%)
Day’s Range― - ―
52-Week RangeAU$0.70 - AU$1.70
Previous CloseN/A
Volume2.26M
Average Volume (3M)820.75K
Market Cap
AU$210.26M
Enterprise ValueAU$160.03M
Total Cash (Recent Filing)AU$44.37M
Total Debt (Recent Filing)AU$835.79K
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding271,307,950
10 Day Avg. Volume747,972
30 Day Avg. Volume820,745
Financial Highlights & Ratios
PEG Ratio-3.76
Price to Book (P/B)18.08
Price to Sales (P/S)34.89
P/FCF Ratio-29.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.15Price Target Upside41.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$14.15M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth (19.6% reported) indicates expanding product uptake and market penetration. Over 2–6 months this supports reinvestment in sales, clinical evidence and manufacturing scale, improving long-term ability to convert revenue into sustainable operations.
Low Leverage / Strong Capital StructureVery low debt-to-equity (0.04) and a healthy equity ratio provide balance sheet flexibility, lowering refinancing and solvency risk. This conservatism supports multi-month operational runway and strategic investments without large interest burdens.
Commercial & Manufacturing CapabilitiesOwning product sales channels and cell-therapy manufacturing capabilities creates multiple, operational revenue streams (devices, processing fees, services). This vertical capability aids quality control, margin capture and durable commercialisation in orthopaedic markets.
Bears Say
Persistent UnprofitabilityOngoing negative margins and losses limit the company's capacity to self-fund growth, erode returns on equity and constrain strategic optionality. Over months this pressures cash needs, raises reliance on external funding and can impede long-term R&D or commercial expansion.
Negative Operating Cash FlowEven with improved free cash flow growth, negative operating cash flow signals continuing cash burn from core operations. This structural cash gap forces dependence on financing or equity raises, which can dilute stakeholders and limit consistent investment in manufacturing or market development.
Regulatory And Reimbursement DependencyRevenue and adoption hinge on regulatory clearances, reimbursement decisions and surgeon uptake. These external, structural hurdles create multi-month uncertainty for market access, volume scaling and pricing power, making revenue trajectories and margins contingent on third-party actions.
Orthocell Ltd News
OCC FAQ
What was Orthocell Ltd’s price range in the past 12 months?
Orthocell Ltd lowest share price was AU$0.70 and its highest was AU$1.70 in the past 12 months.
What is Orthocell Ltd’s market cap?
Orthocell Ltd’s market cap is AU$210.26M.
When is Orthocell Ltd’s upcoming earnings report date?
Orthocell Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 154 days.
How were Orthocell Ltd’s earnings last quarter?
Orthocell Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.021.
Is Orthocell Ltd overvalued?
According to Wall Street analysts Orthocell Ltd’s price is currently Undervalued.
Does Orthocell Ltd pay dividends?
Orthocell Ltd does not currently pay dividends.
What is Orthocell Ltd’s EPS estimate?
Orthocell Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orthocell Ltd have?
Orthocell Ltd has 271,307,950 shares outstanding.
What happened to Orthocell Ltd’s price movement after its last earnings report?
Orthocell Ltd reported an EPS of -AU$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Orthocell Ltd?
Currently, no hedge funds are holding shares in AU:OCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthocell Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.15 (41.98% Upside)
AU$1.15 (41.98% Upside)
Blogger Sentiment
Bullish
AU:OCC Sentiment 98%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$56.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.48%
12-Months-Change
Fundamentals
Return on Equity
-44.80%
Trailing 12-Months
Asset Growth
49.36%
Trailing 12-Months
Company Description
Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
OCC Stock 12 Month Forecast
Average Price Target
AU$1.15
▲(41.98% Upside)
Technical Analysis
Paradigm Biopharmaceuticals
―
Immutep Ltd
―
Dimerix Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---